Software Development Is Now a Capitalized Cost: How Section 174 Reaches Beyond the Lab

Key takeaways

• IRC § 174, as amended by the Tax Cuts and Jobs Act, requires capitalization and amortization of all specified research and experimental costs beginning in tax years after December 31, 2021 — current-year deduction is gone.
• The scope is broader than the R&D tax credit: routine software development costs that once qualified for expensing under Rev. Proc. 2000-50 are now swept into § 174.
• Domestic costs amortize over five years (15 years for foreign-conducted research), on a mid-year convention, creating a first-year deduction of only 10% of the qualifying spend.
• Companies that budgeted for current deductions and did not model this change face a real taxable-income increase in 2022 — without any change in their underlying economics.

What changed and why software companies should care first

Before 2022, § 174 permitted businesses to either deduct research and experimental expenditures currently or capitalize and amortize them at the taxpayer's election. Most companies deducted them currently. That option is eliminated.

The TCJA's § 13206 amended IRC § 174 to make capitalization mandatory, effective for tax years beginning after December 31, 2021. Congress included a two-year amortization period for domestic costs — five years on a straight-line basis with a half-year mid-year convention. The practical effect: a company spending $2 million on qualifying domestic R&E in 2022 may deduct only $200,000 this year.

Revenue Procedure 2000-50, which allowed current deduction of software development costs under a separately developed IRS position, is now obsolete for software that qualifies as specified research and experimental expenditure under § 174. The IRS has not issued detailed guidance formally superseding Rev. Proc. 2000-50 as of this writing, but the statutory text of § 174 controls. Software companies that built planning around that revenue procedure face the starkest disruption.

The scope question: what is "specified research or experimental expenditure"

The statute uses the same scope language as pre-TCJA § 174 — costs paid or incurred in connection with the taxpayer's trade or business that represent research or experimentation in the experimental or laboratory sense. That language has never been narrow in practice, and IRS guidance under the prior law interpreted it broadly to include:

• costs of developing or improving products or processes
• pilot models, formulas, inventions, and similar property
• software development costs for internal use and for sale or license

The key boundary question — whether routine software development for internal operations falls within the scope of § 174 as amended — is not yet resolved by guidance issued as of February 2022. Until it is, defensible practice treats in-scope software development costs as presumptively subject to capitalization unless a clear exclusion applies.

Mechanics that matter for 2022 planning

The mid-year convention is not the taxpayer's friend

Domestic R&E costs must be amortized beginning at the midpoint of the tax year in which they are paid or incurred. For a calendar-year company incurring $1 million of qualifying domestic costs ratably through 2022, the first-year deduction is $100,000 — 10% of the spend.

Years two through five receive equal installments of 20%, with year six receiving the remaining 10%. Total deduction over the five-year period is 100%, but the front-loading of cash-tax cost is significant.

Foreign R&E costs are worse

Costs attributed to research conducted outside the United States are amortized over 15 years using the same mid-year convention. Companies with offshore engineering or product development teams face substantially more deferred deduction.

The R&D credit does not offset the damage

The § 41 research credit provides a dollar-for-dollar credit against tax liability for qualifying research expenses, subject to the credit's own eligibility rules. That credit remains available. But the § 41 credit and the § 174 capitalization requirement operate on different base amounts and different timelines. The credit does not eliminate the cash-tax increase from deferred deductions — it reduces it for companies with qualifying activity, but many businesses affected by § 174 do not have substantial § 41 credit claims.

What finance and tax teams should do now

Identify the exposed spend. The starting point is a line-item review of R&D, software development, engineering, and related cost centers to distinguish currently deductible costs from those now subject to § 174 capitalization. This is not a routine year-end reconciliation — it requires a scope analysis.

Revise 2022 quarterly estimates. For pass-through entities, this means the owners' individual estimates. For C-corps, it means re-running the effective rate computation against the revised taxable income projection. Underpayment penalties apply to estimates that fail to reflect higher taxable income — that exposure starts accumulating with Q1.

Communicate with lenders. Debt covenants tied to taxable income, effective tax rate, or cash flow from operations may be sensitive to the 2022 change. Lenders who have not been briefed on the § 174 impact should be engaged proactively, before the year-end financial statements raise questions.

Do not assume legislative relief. Bipartisan support for restoring current deductibility exists in Congress, and proposals to reverse or defer the § 174 amendment have been introduced. As of February 2022, none has been enacted. Planning must reflect current law.

Bottom line

Section 174 is not a technical footnote. For software businesses and R&D-intensive companies, it is the most consequential single tax-law change of 2022 — producing a real cash-tax increase without any corresponding change in business performance. The companies positioned to manage it are the ones that identified the exposure before the first quarterly estimate was due.